Echo Therapeutics (NSDQ:ECTE) said today it began stand-alone component and integrated testing of its NextGen continuous glucose monitoring system prototypes and selected a clinical research organization to aid it in arranging a regulatory and clinical strategy.
The Iselin, N.J.-based company is developing a non-invasive, wireless CGM for use in the outpatient diabetes market and the fitness, weight loss and personal lifestyle wearable-health space
“I am excited about the progress our development team has made in the development and testing of the NextGen components and on integrating them into a system. We received very positive feedback from our demonstration of the NextGen self-exfoliator and app at the 2016 American Diabetes Association Scientific Sessions in New Orleans this month. We look forward to collaborating with our experienced CRO on the clinical development and regulatory pathway of our technology,” CEO Scott Hollander said in a press release.
Echo Therapeutics said it began hardware and software testing of its NextGen Exfoliator and bluetooth transmitter as well, and is continuing testing of the NextGen sensor element and hydrogel. Testing of the company’s API and software application have been completed.
Earlier this month, Echo Therapeutics said it won Institutional Review Board approval to expand testing of its non-invasive continuous glucose monitor, which can now include both pediatric and adult subjects.
Last July, Echo Therapeutics said it is moving its research lab from Franklin, Mass. to Littleton, Mass. and terminating its previous lease in the process.
The developer of wireless glucose monitors and wearable health and fitness devices said it paid $150,000 to break the lease on its previous 37,050 square foot research facility in Franklin. Echo Therapeutics relocated on July 3 to a smaller 10,132 square foot research facility in Littleton, Mass., according to an SEC filing from the company.